Wedbush Keeps a Buy Rating on Millendo Therapeutics Inc (MLND)

By Ryan Adsit

Wedbush analyst Laura Chico reiterated a Buy rating on Millendo Therapeutics Inc (MLNDResearch Report) yesterday and set a price target of $24. The company’s shares closed last Monday at $6.97, close to its 52-week low of $6.77.

According to TipRanks.com, Chico is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.2% and a 41.5% success rate. Chico covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Dova Pharmaceuticals Inc, and Prevail Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Millendo Therapeutics Inc with a $24 average price target.

See today’s analyst top recommended stocks >>

Based on Millendo Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.87 million. In comparison, last year the company had a GAAP net loss of $7.7 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Millendo Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in the development of novel treatments for endocrine diseases. Its products include livoletide and nevanimibe. The company was founded in April, 2011 and is headquartered in Ann Arbor, MI.